Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Jorde, UP; Aaronson, KD; Najjar, SS; Pagani, FD; Hayward, C; Zimpfer, D; Schlöglhofer, T; Pham, DT; Goldstein, DJ; Leadley, K; Chow, MJ; Brown, MC; Uriel, N.
Identification and Management of Pump Thrombus in the HeartWare Left Ventricular Assist Device System: A Novel Approach Using Log File Analysis.
JACC Heart Fail. 2015; 3(11):849-56
Doi: 10.1016/j.jchf.2015.06.015
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Zimpfer Daniel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES: The study sought to characterize patterns in the HeartWare (HeartWare Inc., Framingham, Massachusetts) ventricular assist device (HVAD) log files associated with successful medical treatment of device thrombosis. BACKGROUND: Device thrombosis is a serious adverse event for mechanical circulatory support devices and is often preceded by increased power consumption. Log files of the pump power are easily accessible on the bedside monitor of HVAD patients and may allow early diagnosis of device thrombosis. Furthermore, analysis of the log files may be able to predict the success rate of thrombolysis or the need for pump exchange. METHODS: The log files of 15 ADVANCE trial patients (algorithm derivation cohort) with 16 pump thrombus events treated with tissue plasminogen activator (tPA) were assessed for changes in the absolute and rate of increase in power consumption. Successful thrombolysis was defined as a clinical resolution of pump thrombus including normalization of power consumption and improvement in biochemical markers of hemolysis. Significant differences in log file patterns between successful and unsuccessful thrombolysis treatments were verified in 43 patients with 53 pump thrombus events implanted outside of clinical trials (validation cohort). RESULTS: The overall success rate of tPA therapy was 57%. Successful treatments had significantly lower measures of percent of expected power (130.9% vs. 196.1%, p = 0.016) and rate of increase in power (0.61 vs. 2.87, p < 0.0001). Medical therapy was successful in 77.7% of the algorithm development cohort and 81.3% of the validation cohort when the rate of power increase and percent of expected power values were <1.25% and 200%, respectively. CONCLUSIONS: Log file parameters can potentially predict the likelihood of successful tPA treatments and if validated prospectively, could substantially alter the approach to thrombus management.
- Find related publications in this database (using NLM MeSH Indexing)
- Clinical Trials as Topic - administration & dosage
- Fibrinolytic Agents - administration & dosage
- Heart Failure - therapy
- Heart Transplantation - administration & dosage
- Heart-Assist Devices - adverse effects
- Humans - administration & dosage
- Thrombosis - drug therapy, etiology
- Tissue Plasminogen Activator - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- HeartWare ventricular assist device
- pump thrombosis
- thrombus
- tissue plasminogen activator
- thrombolytics